Category Archives: Cell Therapy

Cell Therapy News is an online publication and email newsletter dedicated to sharing the latest cell therapy, gene therapy, and regenerative medicine research.
Subscribe
Published weekly since 2002, Cell Therapy News is our longest running online publication. Our editorial team curates the top publications, reviews, and news on in vivo gene therapy, cell therapy, and immunotherapy research. With over 15,000 subscribers and followers across our website, email newsletter, and Twitter feed, we are proud to facilitate the communication of cutting-edge cell therapy innovations.

A Novel Non-Viral Delivery Method That Enables Efficient Engineering of Primary Human T Cells for Ex Vivo Cell Therapy Applications

The Solupore system was used to deliver mRNA and CRISPR/Cas9 guide RNA ribonucleoprotein cargos to T cells, and efficiency was measured by flow cytometry.
[Cytotherapy]
Kavanagh, H., Dunne, S., Martin, D. S., McFadden, E., Gallagher, L., Schwaber, J., Leonard, S., & O’Dea, S. (2021). A novel non-viral delivery method that enables efficient engineering of primary human T cells for ex vivo cell therapy applications. Cytotherapy, 0(0). https://doi.org/10.1016/j.jcyt.2021.03.002 Cite
Full Article
Bookmark

No account yet? Register

0
Share

LILRB4 Suppresses Immunity in Solid Tumors and Is a Potential Target for Immunotherapy

The authors observed a high correlation in LILRB4 expression with other immune inhibitory receptors. After tumor challenge, LILRB4−/− mice and mice treated with anti-LILRB4 antibody showed reduced tumor burden and increased survival.
[Journal of Experimental Medicine]
Sharma, N., Atolagbe, O. T., Ge, Z., & Allison, J. P. (2021). LILRB4 suppresses immunity in solid tumors and is a potential target for immunotherapy. Journal of Experimental Medicine, 218(e20201811). https://doi.org/10.1084/jem.20201811 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Isolation and Expansion of Thymus-Derived Regulatory T Cells for Use in Pediatric Heart Transplant Patients

High levels of FOXP3, CTLA4 and CD25 expression, demethylation of the FOXP3 promoter and high suppressive ability were found with no differences between Tregs and RA+Tregs.
[European Journal of Immunology]
Romano, M., Sen, M., Scottà, C., Alhabbab, R. Y., Rico‐Armada, A., Lechler, R. I., Burch, M., & Lombardi, G. (n.d.). Isolation and expansion of thymus-derived regulatory T cells for use in paediatric heart transplant patients. European Journal of Immunology, n/a(n/a). https://doi.org/https://doi.org/10.1002/eji.202048949 Cite
Abstract
Bookmark

No account yet? Register

0
Share

A Stem Cell Population at the Anorectal Junction Maintains Homeostasis and Participates in Tissue Regeneration

The authors identified a population of Krt17+ basal cells with multipotent properties at the squamo-columnar anorectal junction that maintained a squamous epithelium during normal homeostasis and could participate in the repair of a glandular epithelium following tissue injury.
[Nature Communications]
Mitoyan, L., Chevrier, V., Hernandez-Vargas, H., Ollivier, A., Homayed, Z., Pannequin, J., Poizat, F., De Biasi-Cador, C., Charafe-Jauffret, E., Ginestier, C., & Guasch, G. (2021). A stem cell population at the anorectal junction maintains homeostasis and participates in tissue regeneration. Nature Communications, 12(1), 2761. https://doi.org/10.1038/s41467-021-23034-x Cite
Full Article
Bookmark

No account yet? Register

0
Share

Brief In Vitro IL-12 Conditioning of CD8+ T Cells for Anticancer Adoptive T Cell Therapy

Scientists summarize studies that indicate the superiority of IL-12 as a potential cytokine for conditioning T cells for adoptive cell therapy.
[Cancer Immunology Immunotherapy]
Salem, M. L., Salman, S., & Barnawi, I. O. (2021). Brief in vitro IL-12 conditioning of CD8 + T Cells for anticancer adoptive T cell therapy. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-021-02887-7 Cite
Abstract
Bookmark

No account yet? Register

0
Share

The Therapeutic Potential of Hematopoietic Stem Cells in Bone Regeneration

Investigators highlight the influence of hematopoeitic stem cells in the bone repair process, mainly through the promotion of osteogenesis and angiogenesis at the bone injury site.
[Tissue Engineering Part B-Reviews]
Oliveira, C. S., Carreira, M., Correia, C. R., & Mano, J. F. (2021). The Therapeutic Potential of Hematopoietic Stem Cells in Bone Regeneration. Tissue Engineering Part B: Reviews. https://doi.org/10.1089/ten.teb.2021.0019 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Accelerated Biosciences’ Immune-Privileged Human Trophoblast Stem Cells (hTSCs) Offer Breakthrough Opportunities in Cancer-Targeting Therapeutics and Regenerative Medicine Treatments

Accelerated Biosciences announced new data that further demonstrates statistically significant cytolysis with iPSc-derived natural killer cells programmed from its ethically sourced hTSCs.
[Accelerated Biosciences (BusinessWire, Inc.)]
Press Release
Bookmark

No account yet? Register

0
Share

Autologous Ex Vivo Lentiviral Gene Therapy for Adenosine Deaminase Deficiency

Scientists treated 50 patients with Severe combined immunodeficiency due to adenosine deaminase (ADA) with an investigational gene therapy composed of autologous CD34+ hematopoietic stem and progenitor cells transduced ex vivo with a self-inactivating lentiviral vector encoding human ADA.
[New England Journal of Medicine]
Kohn, D. B., Booth, C., Shaw, K. L., Xu-Bayford, J., Garabedian, E., Trevisan, V., Carbonaro-Sarracino, D. A., Soni, K., Terrazas, D., Snell, K., Ikeda, A., Leon-Rico, D., Moore, T. B., Buckland, K. F., Shah, A. J., Gilmour, K. C., De Oliveira, S., Rivat, C., Crooks, G. M., … Gaspar, H. B. (2021). Autologous Ex Vivo Lentiviral Gene Therapy for Adenosine Deaminase Deficiency. New England Journal of Medicine, 0(0), null. https://doi.org/10.1056/NEJMoa2027675 Cite
AbstractPress Release
Bookmark

No account yet? Register

0
Share

Removal of CD276+ Cells from Haploidentical Memory T-Cell Grafts Significantly Lowers the Risk of GVHD

Analysis of CD45RA-depleted haploidentical mixed lymphocytes culture revealed insufficient suppression of alloresponses in the CD4+ compartment and identified CD276 as a marker for alloreactive memory Th1 T cells.
[Bone Marrow Transplantation]
Hashimoto, H., Kasteleiner, P., Kressin, J., Müller, F., Bühring, H.-J., Handgretinger, R., & Schilbach, K. (2021). Removal of CD276 + cells from haploidentical memory T-cell grafts significantly lowers the risk of GVHD. Bone Marrow Transplantation, 1–19. https://doi.org/10.1038/s41409-021-01307-9 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Engineered Red Blood Cells as an Off-the-Shelf Allogeneic Anti-Tumor Therapeutic

Researchers engineered red blood cells into artificial antigen-presenting cells presenting a peptide bound to the major histocompatibility complex I, the costimulatory ligand 4-1BBL, and interleukin-12.
[Nature Communications]
Zhang, X., Luo, M., Dastagir, S. R., Nixon, M., Khamhoung, A., Schmidt, A., Lee, A., Subbiah, N., McLaughlin, D. C., Moore, C. L., Gribble, M., Bayhi, N., Amin, V., Pepi, R., Pawar, S., Lyford, T. J., Soman, V., Mellen, J., Carpenter, C. L., … Chen, T. F. (2021). Engineered red blood cells as an off-the-shelf allogeneic anti-tumor therapeutic. Nature Communications, 12(1), 2637. https://doi.org/10.1038/s41467-021-22898-3 Cite
Full Article
Bookmark

No account yet? Register

0
Share

CRISPR Therapeutics, Nkarta to Jointly Develop Engineered Natural Killer Cells as Cancer Treatments

Off-the-shelf treatments for cancer made from genetically engineered T cells and natural killer, or NK, cells have each shown promise in clinical trials. Two biotech companies- Nkarta and CRISPR Therapeutics- announced a partnership that aims to merge the two immune-cell approaches together.
[STAT News]
Press Release
Bookmark

No account yet? Register

0
Share
Share